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Supplementary table 1. 
 
STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies  
 Item 
No Recommendation Page/line 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
3/63 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
3 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
4 & 5 
Objectives 3 State specific objectives, including any prespecified hypotheses 5 
Methods  
Study design 4 Present key elements of study design early in the paper 6/146-
161 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
6/146-
161 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants 
6/146-
161 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
6 & 7 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group 
6 & 7 
Bias 9 Describe any efforts to address potential sources of bias 6/146-
161 
Study size 10 Explain how the study size was arrived at 6/154 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
9 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
9 
(b) Describe any methods used to examine subgroups and interactions 9 
(c) Explain how missing data were addressed NA 
(d) If applicable, describe analytical methods taking account of sampling 
strategy 
NA 
(e) Describe any sensitivity analyses NA 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
10 
(b) Give reasons for non-participation at each stage NA 
(c) Consider use of a flow diagram NA 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
10 
(b) Indicate number of participants with missing data for each variable of 
interest 
10 
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Outcome data 15* Report numbers of outcome events or summary measures 10 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
10 
(b) Report category boundaries when continuous variables were 
categorized 
NA 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
NA 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
NA 
Discussion  
Key results 18 Summarise key results with reference to study objectives 20 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
21 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
21 & 22 
Generalisability 21 Discuss the generalisability (external validity) of the study results 21 & 22 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present article 
is based 
23 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available 
at www.strobe-statement.org. 
